Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Clinical trial NCT07071961 · SUSPENDED
Trial details
- NCT number
- NCT07071961
- Sponsor
- M.D. Anderson Cancer Center
- Status
- SUSPENDED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-11
- Primary completion
- 2027-05-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.